Compare INVE & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVE | ENTX |
|---|---|---|
| Founded | 1990 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.1M | 62.6M |
| IPO Year | 1997 | 2015 |
| Metric | INVE | ENTX |
|---|---|---|
| Price | $5.15 | $1.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.50 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 324.9K | 124.9K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $60,219,000.00 | $42,000.00 |
| Revenue This Year | $22.10 | N/A |
| Revenue Next Year | $20.74 | N/A |
| P/E Ratio | ★ N/A | $5.44 |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $3.08 | $0.91 |
| 52 Week High | $5.30 | $3.22 |
| Indicator | INVE | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 72.19 | 55.67 |
| Support Level | $3.25 | $1.12 |
| Resistance Level | N/A | $1.38 |
| Average True Range (ATR) | 0.32 | 0.10 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 90.03 | 76.67 |
Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.